TREM-1

TREM-1

TREM-1 詳細

Molecule Name
Triggering receptor expressed on myeloid cells 1
分子の別称
TREM1,CD354
Drug Development Progress
治験薬の数6
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
Triggering Receptor Expressed On Myeloid Cells 1,CD354 Antigen,Triggering Receptor Expressed on Myeloid Cells-1,TREM-1,TREM1,CD354,Triggering receptor expressed on monocytes 1
バックグランド
Triggering receptor expressed on myeloid cells 1 (TREM1) is also known as CD antigen CD354, and is a type I transmembrane protein with a single Ig-like domain. TREM1 is highly expressed in adult liver, lung and spleen than in corresponding fetal tissue. TREM-1 / CD354 stimulates neutrophil and monocyte-mediated inflammatory responses, and also triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. TREM1 can interacts with TYROBP / DAP12.

TREM-1 製品リスト

Species
  • Human(1)
Tag
  • Fc Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • Yes(1)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
TREM-1
Human TREM-1 / CD354 Protein, Fc Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISABLI

$395.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
NangibotideLR-12Phase 2 ClinicalInotrem
Coronavirus Disease 2019 (COVID-19); Shock, Septic
詳細
ABBV-8736ABBV-8736Phase 2 ClinicalAbbvie Inc
Crohn Disease; Inflammatory Bowel Diseases
詳細
TREM-1 antibody (Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Autoimmune Diseases
詳細
CEL383CEL-383Phase 1 ClinicalCelsius Therapeutics Inc
Inflammatory Bowel Diseases
詳細
TREM 1 antibody(Boehringer Ingelheim International Gmbh)TREM 1 antibody(Boehringer Ingelheim International Gmbh)Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Immune System Diseases
詳細
PY-159PY-159Phase 1 ClinicalCentre for the Commercialization of Antibodies and Biologics
Neoplasms; Solid tumours
詳細
Customer Reviews